TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02318225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Study: NCT00105885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telephone care
Description: Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
Study: NCT00787943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 10.0% cream - Formulation 1
Description: Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 10.0% cream - Formulation 1
Description: Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 10.0% cream - Formulation 2
Description: Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 10.0% cream - Formulation 2
Description: Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Study: NCT04012320

Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention, observational study

Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention, observational study
Study: NCT01637493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
Study: NCT03941938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate reinforcement
Description: Anastomosis Reinforcement with with nebulization of 1cc of glue on the anastomosis line

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No reinforcement
Description: Nothing applied on the anastomosis line
Study: NCT02037061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT02440906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Directed Wellness Account
Description: The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Navigator
Description: The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.
Study: NCT05608720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Booklet
Description: Information Booklet prior to the dental visit
Study: NCT00396227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: vildagliptin as add-on to metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiazolidinedione (TZD)
Description: TZD add-on to metformin
Study: NCT01951482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/cisplatin
Description: receive Pemetrexed/cisplatin every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Pemetrexed/cisplatin
Description: receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days
Study: NCT03468023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short arm cast
Description: Application of a below-elbow cast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long arm cast
Description: Application of an above-elbow cast
Study: NCT01004146

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Incentive Spirometry
Description: helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry
Description: helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
Study: NCT01245894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose Rosuvastatin
Description: Rosuvastatin 5mg/day for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose Rosuvastatin
Description: Rosuvastatin 40mg/day for one year
Study: NCT03403101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: Patients are planned to receive the SIRIOX regimen including S-1 (BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; oral twice daily on days 1-7, days 15-21）of every cycle.~• 28 days a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Patients are planned to receive the SIRIOX regimen including Oxaliplatin (OXA, 85 mg/m2; d1,d15) of every cycle.~• 28 days a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle.~• 28 days a cycle
Study: NCT03647943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation, involving low-levels of electrical stimulation applied to the right and left DLPFC will be used in conjunction with cognitive training for 46 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Sham transcranial direct current stimulation, involving no electrical stimulation will be used in conjunction with cognitive training for 46 minutes.
Study: NCT03959618

Intervention type: OTHER
Intervention: dietary supplements questionary
Description: Patient Questionary Patient to be carried out at the last cure
Study: NCT00400946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Study: NCT02783846

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: receive equal volume of normal saline
Study: NCT02030535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: free combination with tiotropium
Study: NCT02783846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 0.5 µg/kg
Description: receive dexmedetomidine 0.5 µg/kg
Study: NCT01347697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction with an acellular porcine dermal collagen implant (biological mesh)
Description: Reconstruction of floor of lesser pelvis with an acellular porcine dermal collagen implant (biological mesh) after extended excision of rectum including levator muscles in advanced low rectal cancer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reconstruction with a gluteus maximus myocutaneous flap
Description: Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
Study: NCT01176851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Single administration of Glyco pMDI 100 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Single administration of Glyco pMDI 100 µg after charcoal ingestion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Single intravenous injection of glycopyrrolate 100 µg
Study: NCT02125929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open surgery
Description: Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
Study: NCT01666873

Intervention type: PROCEDURE
Intervention: patients that undergo a total knee prosthesis
Study: NCT02296840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 10mg/kg/day every 6-8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone-Acetaminophen
Description: Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
Study: NCT01873742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STIC feedback system
Description: This condition includes the use of the STIC feedback system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STIC feedback system
Description: This condition includes the use of the STIC feedback system.
Study: NCT03558321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic guided fractional curretage
Description: Under general anaesthesia , evaluation of the endometrial cavity was done followed by biopsy of the whole endometrial tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection
Description: Through abdominal incision , removal of the whole uterus , both tubes and ovaries and in some cases pelvic lymph nodes removal was done
Study: NCT02612077

Intervention type: OTHER
Intervention: Observational Chemotherapy
Description: No intervention - Observational standard practice chemotherapy

Intervention type: DRUG
Intervention: Concomitant Bevacizumab
Description: No intervention - Observational concomitant bevacizumab
Study: NCT02461732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)
Description: Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Substance Dependence
Description: Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities
Study: NCT00349791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System
Description: testosterone (300 mcg/day) patch replaced twice a week for two years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch replaced twice a week for two years
Study: NCT02974946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard
Study: NCT02575313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Food Intervention
Description: A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
Study: NCT03939130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Consumption of 1.0g / kg of body mass / day of fructose.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Consumption of 1.0g / kg of body mass / day of glucose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose and exercise
Description: Consumption of 1.0g / kg of body mass / day of fructose + 3 weekly sessions of 60 minutes of aerobic exercise.
Study: NCT03120403

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Study: NCT01985685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiamine
Description: 200 mg IV thiamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: 200 mg IV thiamine
Study: NCT03330743

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent Mentor with Standard Education
Description: Parent mentors will provide coaching based on the current guidelines around diet and physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Mentor with Positive Deviance
Description: Parent mentors will provide coaching based on findings from the positive deviance study
Study: NCT00607828

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo radiotherapy
Study: NCT01863563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickClot
Description: 1 application of treatment to each tonsil/adenoid removal area
Study: NCT02030535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: free combination with olodaterol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: fixed dose combination with olodaterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: fixed dose combination with tiotropium
Study: NCT05937126

Intervention type: DIAGNOSTIC_TEST
Intervention: FilmArray Pneumonia Panel
Description: FDA-approved/cleared molecular, multiplex device that rapidly identifies viruses, bacteria, and antimicrobial resistance genes in sputum-like and bronchoalveolar lavage (BAL)-like specimens obtained from individuals with signs of a lower respiratory tract infection.

Intervention type: DIAGNOSTIC_TEST
Intervention: Culture and antimicrobial susceptibility testing
Description: Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.

Intervention type: DIAGNOSTIC_TEST
Intervention: Culture and antimicrobial susceptibility testing
Description: Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.
Study: NCT04151368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Nipple-Sparing Mastectomy (RNSM)
Description: RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
Study: NCT00078923

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Prostatectomy or Brachytherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Prostatectomy or Brachytherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Prostatectomy or Brachytherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
Study: NCT03891095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasally administrated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOPA
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: intranasally administrated and orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: intranasally administrated and orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: intranasally administrated and orally administered
Study: NCT02783846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 1.0 µg/kg
Description: receive dexmedetomidine 1.0 µg/kg
Study: NCT00637871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: 150mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Study: NCT04208581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue Huatan granule
Description: Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Yiqi Huoxue Huatan granule
Description: Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
Study: NCT05541068

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioimpedance analysis
Description: Bioimpedance analysis to achieve assessments of fluid status, especially dry-weight, was performed with the portable Biomasc touch i8 (MaltronInternationl, Essex, UK).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioimpedance analysis
Description: Bioimpedance analysis to achieve assessments of fluid status, especially dry-weight, was performed with the portable Biomasc touch i8 (MaltronInternationl, Essex, UK).
Study: NCT01732003

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Complete

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Study: NCT03129256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate tablet combined with S-1 capsules
Description: Oral use with low-dose Apatinib combined with S-1 until disease progression
Study: NCT03457194

Intervention type: BIOLOGICAL
Intervention: Quadrivalent Influenza Vaccine
Description: Inactivated quadrivalent influenza vaccine that is used for active immunisation against influenza A, B virus strains (contained in vaccine). Single dose administration by intramuscular injection to all enrolled pregnant women as part of routine antenatal care.

Intervention type: BIOLOGICAL
Intervention: DTP Vaccine (Multiple Actives)
Description: Pertussis vaccine acellular combined with diphtheria and tetanus toxoids. Single dose administration by intramuscular injection, to all enrolled pregnant women who are 28 weeks or greater gestation at time of enrolment, as part of routine antenatal care.